Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Eye Injuries, Critically Ill
Interventions
plastic wrap over eye & lubrication applied q6 hrs
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Weeks to 17 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2007 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Respiratory Failure, Respiratory Infection, Aspiration Pneumonia, Pneumonitis, Atelectasis, Bronchospasm
Interventions
Neuromuscular Blocking Agents, Anesthetic Adjuncts
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Target Drug-related Adverse Events
Interventions
Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
Other
Lead sponsor
InSource Diagnostics
Industry
Eligibility
12 Years and older
Enrollment
14,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Tazewell, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Glabellar Rhytides, Frown Lines Between the Eyebrows
Interventions
Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced May 22, 2026, 5:19 AM EDT
Not yet recruiting Not applicable Interventional
Conditions
Neuromuscular Blockade Monitoring, Neuromuscular Monitoring After Administration of Neuromuscular Blocking Agents in Different Types of Surgery
Interventions
NMT Technology
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Allergy
Interventions
Skin Testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
Interventions
venlafaxine XR, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced May 22, 2026, 5:19 AM EDT
Conditions
HR+ HER2- Breast Cancer
Interventions
Serabelisib, Sapanisertib, Fulvestrant
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Los Angeles, California • Springfield, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 22, 2026, 5:19 AM EDT
Conditions
General Surgery
Interventions
Sugammadex, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2010 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Neuromuscular Blockade, Residual Curarisation, Postoperative, Surgery Under General Anaesthesia
Interventions
Neuromuscular blocking agents
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
265,537 participants
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative
Interventions
Sugammadex, Neostigmine, Glycopyrrolate, Rocuronium
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Healthy
Interventions
CW 002
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 49 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced May 22, 2026, 5:19 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 22, 2026, 5:19 AM EDT
Completed No phase listed Observational
Conditions
Acute Respiratory Distress Syndrome, Acute Respiratory Failure With Hypoxia, Acute Respiratory Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Advanced Solid Tumors, Advanced Breast Cancer
Interventions
ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
Drug
Lead sponsor
Ensem Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 5:19 AM EDT
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Glabellar Rhytides
Interventions
Mentor Purified Toxin Botulinum Toxin Type A
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced May 22, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available
Conditions
Postoperative Urinary Retention
Interventions
Sugammadex
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Advanced Solid Tumours
Interventions
Ceralasertib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Haematologic Neoplasms
Interventions
AZD2962
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 22, 2026, 5:19 AM EDT
Conditions
Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
27
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 22, 2026, 5:19 AM EDT